Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab β plus chemotherapy in metastatic colorectal cancer (RAS/BRAF wild-type)
ChiCTR2500107618Phase 4Not yet recruiting
- Sponsor
- Chongqing Qianjiang Central Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Chongqing Qianjiang Central Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500107618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107618.